Mechanism of Action
Multi-Target Lipid II and Lipid III Binding
Teixobactin binds the pyrophosphate-sugar moiety of Lipid II (inhibiting peptidoglycan synthesis, like vancomycin) and simultaneously binds Lipid III (undecaprenyl pyrophosphate, also the bacitracin target), inhibiting cell wall precursor transport. This dual targeting depletes both substrates of the peptidoglycan assembly machinery. The binding is achieved through a unique beta-sheet assembly of multiple teixobactin molecules that oligomerize on the bacterial membrane surface, creating an insoluble complex that sequesters both lipids.
Resistance Resistance Explained
The key prediction for teixobactin was that resistance would be essentially impossible to develop because: (1) it targets non-protein lipids that bacteria cannot easily mutate; (2) the dual target means bacteria would need to simultaneously escape two unrelated essential processes; (3) the conserved pyrophosphate anchor is used by multiple essential cell wall intermediates and is fundamental to bacterial life. Serial passage experiments over 27 days in E. faecalis showed no MIC increase, confirming this prediction in the laboratory.
Research Summary
2015 Nature Paper and Impact
PreclinicalThe Ling et al. 2015 Nature paper describing teixobactin was a landmark event in antibiotic research. It demonstrated the power of uncultured soil bacteria as a source of novel antibiotics and provided the iChip methodology as a tool for mining this vast reservoir. In mouse infection models, teixobactin cleared MRSA and Streptococcus pneumoniae infections at doses of 5 mg/kg. The discovery reinvigorated interest in natural product antibiotic discovery using culture-independent methods.
Synthesis and Analog Development
PreclinicalTotal chemical synthesis of teixobactin was achieved by multiple groups in 2016-2017, enabling SAR studies. The unusual amino acids (allo-Enduracididine, D-amino acids) present synthetic challenges but synthetic routes have been developed. Simplified analogs replacing the unusual Enduracididine with arginine (TXB-COO and similar) retain potent activity and are more synthetically accessible. Preclinical development of these analogs by NovoBiotic Pharmaceuticals and academic groups is ongoing.
Calculate your Teixobactin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| MRSA mouse model | 5-10 mg/kg | Twice daily | IV / SC (research) |
| In vitro susceptibility | 0.25-1 ug/mL MIC (MRSA) | Single exposure | Direct application |
No human data. Synthesis challenges have slowed clinical development. Analogs advancing.
Interactions
Safety Profile
Low cytotoxicity to mammalian cells in vitro due to Gram-positive selective LPS-independent targeting. Animal studies showed no obvious toxicity at therapeutic doses. Synthesis complexity is the primary barrier to clinical development, not projected toxicity. Renal and hepatic safety profiles in animal studies appear acceptable. No human clinical data.
References
- [1]Ling LL, et al. (2015). A new antibiotic kills pathogens without detectable resistance. Nature, 517(7535), 455-459.
- [2]Cochrane SA and Vederas JC. (2016). Lipopeptides from Bacillus and Paenibacillus spp.: a gold mine of antibiotic candidates. Med Res Rev, 36(1), 4-31.